Roche announced in December it would invest more than €200 million (US$266 million) in diagnostics production and create 50 new jobs at its Penzberg biotechnology center near Munich. Plans call for the 26,000-sq.-m. (279,870-sq.-ft.) Diagnostics Operations Complex II to be operational in December 2014.
“This investment in meeting global demand for immunoassays is further evidence of the success of our personalised healthcare strategy,” said Roland Diggelmann, COO of Roche’s Diagnostics Division. “Today’s diagnostics make it possible to detect and differentiate the causes and triggers of chronic illnesses and acute conditions with greater precision than ever before. Modern diagnostic systems can test blood samples from up to 1,000 patients an hour and deliver highly accurate results. Based on laboratory tests, doctors are able to prescribe timely, targeted care for their patients. The new facility will ensure that we can continue to meet the rising demand for reagents.”
To read the full, original article click on this link: Briefly Bio: Bavaria, Montreal, La Jolla, St. Louis, Boston and more. | Site Selection
